April 12, 2018 / 5:23 AM / a year ago

Healthcare group Sanofi to invest 350 mln euros in Canada vaccine facility

PARIS, April 12 (Reuters) - French healthcare group Sanofi is investing 350 million euros ($432.4 million) in a Canadian vaccine facility, which the drugmaker said would help it meet growing demand in this area.

Sanofi’s new investment will finance the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario.

The new facility would allow its Sanofi Pasteur division to meet the growing demand of five-component acellular pertussis (5-acP) antigen, the company added.

Sanofi sealed two major takeovers at the start of 2018, buying haemophilia specialist Bioverativ for $11.6 billion and acquiring Ablynx, which is developing a prized experimental drug for a rare blood disorder, for 3.9 billion euros ($4.8 billion).

$1 = 0.8094 euros Reporting by Sudip Kar-Gupta; Editing by Sunil Nair

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below